The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Figures & data

Table 1 Selected clinical trials testing venetoclax-based regimens in CLL/SLL

Clinical trial ID	Name	Design	Eligibility	Treatment arm(s)
NCT02950051	CLL13 (GAIA)	Phase III, randomized	Fit patients, treatment naïve, TP53/del(17p) excluded	1. FCR or BR 2. VR 3. GV 4. GVI
NCT02242942	CLL14	Phase III, randomized	Unfit patients, treatment naïve, TP53/del(17p) included	1. G-Cbl 2. GV
ISRCTN01844152	FLAIR	Phase III, randomized	Fit patients, treatment naïve, TP53/del(17p) excluded	1. FCR 2. Ibrutinib 3. IR 4. VI
NCT03462719	–	Phase III, randomized	Unfit patients, treatment naïve, TP53/del(17p) excluded	1. G-Cbl 2. VI
NCT02910583	CAPTIVATE-2	Phase II, randomized	Fit patients, treatment naïve, TP53/del(17p) included	1. Ibrutinib 2. VI
ISRCTN13751862	CLARITY	Phase II, single-arm	Prior purine analog therapy, TP53/del(17p) included	1. VI
NCT03379051	–	Phase I/II, single-arm	One prior treatment regimen, TP53/del(17p) included	1. Venetoclax in combination with ublituximab and umbralisib
NCT03534323	–	Phase I/II, single-arm	One prior treatment regimen, TP53/del(17p) included	1. Venetoclax plus duvelisib
NCT02639910	COSMOS	Phase II, single-arm	Prior BTKi therapy, TP53/del(17p) included	1. Venetoclax or idelalisib + MOR208
NCT02427451	–	Phase I/II, single-arm	One prior treatment regimen, TP53/del(17p) included	1. GVI

Notes: Venetoclax-based clinical trials under investigation in CLL/SLL. Further details on specific agents: ublituximab is a novel anti-CD20 antibody, umbralisib is a novel PI3Kδ inhibitor, and MOR208 is a novel anti-CD19 antibody.

Abbreviations: BR, bendamustine, rituximab; BTKi, Bruton’s tyrosine kinase inhibitor; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; FCR, fludarabine, cyclophosphamide, rituximab; G-Clb, obinutuzumab, chlorambucil; GV, obinutuzumab, venetoclax; GVI, obinutuzumab, venetoclax, ibrutinib; IR, ibrutinib, rituximab; VI, venetoclax, ibrutinib; VR, venetoclax, rituximab.